natgillin/translations-raw huggingface dataset:
Always use Filgrastim ratiopharm exactly as your doctor has told you.
KAKO UPORABLJATI ZDRAVILO Filgrastim ratiopharm Pri uporabi zdravila Filgrastim ratiopharm natančno upoštevajte zdravnikova navodila.
MARKETING AUTHORISATION HOLDER ratiopharm GmbH
SHRANJEVANJE ZDRAVILA Filgrastim ratiopharm
Do not use any Filgrastim ratiopharm that is left in the syringe.
Zdravila Filgrastim ratiopharm, ki morebiti ostane v injekcijski brizgi, ne smete več uporabiti.
Special precautions in recipients of allogeneic PBPC mobilised with filgrastim
Pri nekaterih bolnikih s srpasto anemijo, ki so prejemali filgrastim, je
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer Carton
PODATKI NA ZUNANJI OVOJNINI Zunanja ovojnina
Therefore, filgrastim is not indicated for use in these conditions.
Zato ga pri takšnih bolnikih ne smete uporabljati.
Each pre-filled syringe contains 30 MIU (300 µg) of filgrastim in 0.5 ml solution for injection or
(300 µg) filgrastima v 0,5 ml raztopine za
Once the neutrophil nadir has been passed the daily dose of filgrastim should be titrated against the
Ko najnižje število nevtrofilcev preide na višji nivo, je treba koncentracijo dnevnega odmerka filgrastima prilagoditi, da bi se izognili nihanju v številu nevtrofilcev, kot kaže spodnja preglednica:
Headache
SERIJE
> 1.0 x 109/l for 3 consecutive days
0,2 x 106 i.e. (2 μg).
0.375 ml (40 µg/ml) 1 pre-filled pen
0,375 ml (40 µg/ml) 1 napolnjena brizga
0.65 ml (200 µg/ml) 4 pre-filled pens
0,65 ml (200 µg/ml) 4 napolnjene brizge
0.65 ml (200 µg/ml) 1 pre-filled pen
0,65 ml (200 µg/ml) 1 napolnjena brizga
0.375 ml (40 µg/ml) 4 pre-filled syringes with needle guard
0,375 ml (40 µg/ml) 4 napolnjene injekcijska brizge s ščitnikom igle
0.65 ml (200 µg/ml) 4 pre-filled syringes with needle guard
0,65 ml (200 µg/ml) 4 napolnjene injekcijska brizge s ščitnikom igle
0.375 ml (40 µg/ml) 1 pre-filled syringe with needle guard
0,375 ml (40 µg/ml) 1 napolnjena injekcijska brizga s ščitnikom igle
0.65 ml (200 µg/ml) 1 pre-filled syringe with needle guard
0,65 ml (200 µg/ml) 1 napolnjena injekcijska brizga s ščitnikom igle
The full EPAR and risk management plan summary for Aripiprazole Mylan Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Aripiprazol Mylan Pharma sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The name of the medicine was changed to Aripiprazole Mylan Pharma on 3 June 2016.
Ime zdravila je bilo spremenjeno v Aripiprazol Mylan Pharma 3. junija 2016.
Aripiprazole Mylan Pharma is available as tablets (5, 10, 15 and 30 mg) and can only be obtained with a prescription.
Zdravilo Aripiprazol Mylan Pharma je na voljo v obliki tablet (5, 10, 15 in 30 mg) in se izdaja le na recept.
This is a summary of the European public assessment report (EPAR) for Aripiprazole Mylan Pharma.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Aripiprazol Mylan Pharma.
In addition, the company that markets Aripiprazole Mylan Pharma will provide educational materials to be supplied to patients or their caregivers and to doctors to explain the safe use of the medicine in patients between 13 and 17 years.
Poleg tega bo družba, ki trži zdravilo Aripiprazol Mylan Pharma, priskrbela izobraževalno gradivo, ki ga bodo prejeli bolniki ali njihovi negovalci ter zdravniki, v katerem bo pojasnjena varna uporaba zdravila pri bolnikih, starih od 13 do 17 let.
Aripiprazole Mylan Pharma is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults who have responded to the medicine in the past.
Zdravilo Aripiprazol Mylan Pharma se uporablja pri odraslih za zdravljenje zmernih in hudih maničnih epizod ter za preprečevanje pojava novih maničnih epizod pri odraslih, ki so se v preteklosti že odzvali na zdravilo.
The European Commission granted a marketing authorisation valid throughout the European Union for Aripiprazole Pharmathen on 30 June 2015.
Evropska komisija je dovoljenje za promet z zdravilom Aripiprazol Pharmathen, veljavno po vsej Evropski uniji, izdala 30. junija 2015.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Mylan Pharma has been shown to have comparable quality and to be bioequivalent to Abilify.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Aripiprazol Mylan Pharma primerljivo raven kakovosti kot zdravilo Abilify ter da mu je biološko enakovredno.
The Committee recommended that Aripiprazole Mylan Pharma be approved for use in the EU.
Priporočil je, da se zdravilo Aripiprazol Mylan Pharma odobri za uporabo v EU.
Because Aripiprazole Mylan Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Aripiprazol Mylan Pharma generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The dose should be adjusted in patients who are taking other medicines that affect the way Aripiprazole Mylan Pharma is broken down in the body.
Odmerek je treba prilagoditi pri bolnikih, ki jemljejo druga zdravila, ki vplivajo na presnovo zdravila Aripiprazol Mylan Pharma v telesu.
Aripiprazole Mylan Pharma is used in patients with the following mental illnesses:
Zdravilo Aripiprazol Mylan Pharma se uporablja pri bolnikih z naslednjimi duševnimi boleznimi:
This means that Aripiprazole Mylan Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Abilify.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer
What measures are being taken to ensure the safe and effective use of Aripiprazole Mylan Pharma?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Aripiprazol Mylan Pharma?
For more information about treatment with Aripiprazole Mylan Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Aripiprazol Mylan Pharma preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Aripiprazole Mylan Pharma is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Aripiprazol Mylan Pharma je bil pripravljen načrt obvladovanja tveganj.
Aripiprazole Mylan Pharma is used in patients aged 15 years or over;
Zdravilo Aripiprazol Mylan Pharma se uporablja pri bolnikih, starih 15 let ali več;
Because Aripiprazole Mylan Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Abilify.
Ker je zdravilo Aripiprazol Mylan Pharma generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Abilify.
What are the benefits and risks of Aripiprazole Mylan Pharma?
Kakšne so koristi in tveganja, povezani z zdravilom Aripiprazol Mylan Pharma?
For treating manic episodes in bipolar disorder, the recommended starting dose in adults is 15 mg by mouth once a day, either on its own or in combination with other medicines.
Za zdravljenje maničnih epizod pri bipolarni motnji pri odraslih je priporočeni začetni odmerek 15 mg peroralno enkrat na dan, ki se jemlje bodisi kot samostojno zdravilo bodisi v kombinaciji z drugimi zdravili.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aripiprazole Mylan Pharma, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Aripiprazole Mylan Pharma contains the active substance aripiprazole and is a ‘generic medicine'.
Zdravilo Aripiprazol Mylan Pharma vsebuje zdravilno učinkovino aripiprazol in je „generično zdravilo“.
For practical information about using Aripiprazole Mylan Pharma, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Aripiprazol Mylan Pharma naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Previously known as Aripiprazole Pharmathen.
Prej znano kot Aripiprazole Pharmathen.
The active substance in Aripiprazole Mylan Pharma, aripiprazole, is an antipsychotic medicine.
Zdravilna učinkovina v zdravilu Aripiprazol Mylan Pharma, aripiprazol, je antipsihotik.
Other information about Aripiprazole Mylan Pharma
Druge informacije o zdravilu Aripiprazol Mylan Pharma
What is Aripiprazole Mylan Pharma and what is it used for?
Kaj je zdravilo Aripiprazol Mylan Pharma in za kaj se uporablja?
For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day.
Za zdravljenje maničnih epizod pri bolnikih, starih od 13 do 17 let, se jemlje začetni odmerek 2 mg na dan (pri čemer se uporablja zdravilo z aripiprazolom v tekoči obliki), ki se postopoma povečuje na priporočeni odmerek 10 mg enkrat na dan. Zdravljenje ne sme biti daljše od 12 tednov.
Why is Aripiprazole Mylan Pharma approved?
Zakaj je bilo zdravilo Aripiprazol Mylan Pharma odobreno?
How is Aripiprazole Mylan Pharma used?
Kako se zdravilo Aripiprazol Mylan Pharma uporablja?
Aripiprazole Mylan Pharma is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over.
Zdravilo se uporablja tudi za zdravljenje zmernih do hudih maničnih epizod pri bolnikih, starih 13 let ali več, v obdobju do 12 tednov.
How does Aripiprazole Mylan Pharma work?
Kako zdravilo Aripiprazol Mylan Pharma deluje?
How has Aripiprazole Mylan Pharma been studied?
Kako je bilo zdravilo Aripiprazol Mylan Pharma raziskano?
A comprehensive review of the published data was provided.
Predložen je bil izčrpen pregled objavljenih podatkov.
63-100 Śrem POLAND
63-100 Śrem POLJSKA
aureus (skin disease).
aureus (bolezen kože).
Efficacy in target animals
Učinkovitost pri ciljnih živalih
The Committee was also asked to recommend whether the marketing authorisations should be maintained, varied, suspended or withdrawn.
Odbor je bil prav tako zaprošen za priporočilo, ali naj se dovoljenje za promet z zdravilom ohrani, spremeni, začasno umakne ali ukine.
No specific risk to animal health was identified.
Opredeljeno ni bilo nobeno posebno tveganje za zdravje živali.
17170 Amer SPAIN
17170 Amer ŠPANIJA
2050-501 Vila Nova Da Rainha PORTUGAL
2050-501 Vila Nova Da Rainha PORTUGALSKA
Thus, it was possible for the animals to receive the indicated dose of antibiotic.
Zato so lahko živali prejele indicirani odmerek antibiotika.
List of the names, pharmaceutical form, strength of the veterinary medicinal products, animal species, route of administration, applicant/marketing authorisation holders in the Member States
Seznam imen, farmacevtskih oblik, jakosti zdravila za uporabo v veterinarski medicini, živalskih vrst, poti uporabe, predlagateljev/imetnikov dovoljenja za promet z zdravilom v državah članicah
Risk for public health
Tveganje za javno zdravje
Fluoroquinolones have been authorised for use in these species for many years.
Uporaba fluorokinolonov pri teh živalskih vrstah je dovoljena že veliko let.
In summary it may be concluded that today there is sufficient susceptibility to allow adequate treatment against the target animal pathogen Pasteurella.
Če povzamemo, mogoče je sklepati, da zdaj obstaja zadostna občutljivost, ki omogoča ustrezno zdravljenje ciljnega živalskega patogena Pasteurella.
The treatment did not affect the estimated water consumption of animals (about 100 ml/kg body weight).
Zdravljenje ni vplivalo na ocenjeno porabo vode pri živalih (približno 100 ml/kg telesne mase).
These species account for 85% of the animal (meat) production whilst e.g. rabbits only account for 0.7% of the French animal production (EMA, 2011)6, France being one of the biggest rabbit producers in the EU.
Te živalske vrste pomenijo 85 % reje živali (za meso), medtem ko imajo na primer kunci le 0,7-odstoten delež v francoski reji živali (EMA, 2011)6, pri čemer je Francija ena od največjih držav za vzrejo kuncev v EU.
Of the strains examined, 86.67% were susceptible to enrofloxacin, 10% were intermediate and 3.33% were resistant.
Od preučevanih sevov jih je bilo 86,67 % občutljivih za enrofloksacin, 10 % jih je bilo vmesno občutljivih, 3,33 % pa jih je bilo odpornih.
• Official and local antimicrobial policies should be taken into account when the product is used.
• pri uporabi zdravila je treba upoštevati uradne in lokalne protimikrobne politike;
A second pharmacokinetic study was carried out in order to confirm the dose.
Za potrditev tega odmerka je bila opravljena še ena farmakokinetična študija.
411800-282 Lisboa PORTUGAL
411800-282 Lisboa PORTUGALSKA
Sensitivity of various strains of P. multocida was analysed in Spain between 2009 and 2011 and the antibiogram results showed that of a total of 61 P. multocida isolates all 61 strains were sensitive.
Občutljivost različnih sevov P. multocida je bila analizirana v Španiji med letoma 2009 in 2011, rezultati antibiograma pa so pokazali, da je bilo od skupaj 61 izolatov P. multocida občutljivih vseh 61 sevov.
• Whenever possible, fluoroquinolones should only be used based on susceptibility testing.
• fluorokinolone je treba po možnosti uporabljati le na podlagi preskušanja občutljivosti;
Furthermore, as a consequence of restriction on availability, off-label use could be anticipated and this would compromise correct monitoring of use and reporting of adverse reactions.
Poleg tega bi se zaradi omejitve razpoložljivosti lahko pričakovala nenamenska uporaba (off-label use), kar bi ogrozilo ustrezno spremljanje uporabe in poročanje o neželenih učinkih.
Unfortunately, there is insufficient information on the interpretation criteria used on the RESAPATH annual reports.
Žal pa ni dovolj podatkov o merilih za razlago, ki so bila uporabljena v letnih poročilih mreže RESAPATH.
The pharmacokinetic/pharmacodynamic relationship was discussed in relation to the dosage regimens for the clinical trials provided.
O farmakokinetičnem/farmakodinamičnem razmerju se je razpravljalo v povezavi z režimi odmerjanja za predložena klinična preskušanja.
The current knowledge regarding the occurrence of antimicrobial resistance in food animals and the influence of the animal production on its transmission is incomplete.
Sedanje znanje o pojavu protimikrobne odpornosti pri živalih za hrano in vplivu reje živali na njen prenos je nepopolno.
Gran Via Carlos III 98 - 7ª 08028 Barcelona SPAIN
Gran Via Carlos III 98 - 7ª 08028 Barcelona ŠPANIJA
The species for which spread of MRSA would be important is therefore mainly swine (high prevalence) and companion animals (close contact).
Vrste, pri katerih bi bilo širjenje MRSE pomembno, so torej večinoma svinje (velika razširjenost) in hišne živali (tesen stik).
Several MIC data on P. multocida isolated from clinical samples from 30 Spanish rabbit farms in 2006 and 2007 were provided.
Predloženih je bilo več podatkov o MIC za P. multocida, izoliranem iz kliničnih vzorcev iz 30 španskih kunčjih farm v letih 2006 in 2007.
There are no data available that would allow the Committee to estimate the risk for rabbits alone but it seems adequate to allow for the extrapolation of information from poultry and pigs.
Podatkov, ki bi odboru omogočili oceno tveganja samo za kunce, ni, vendar se zdi ustrezno dovoliti ekstrapolacijo podatkov za perutnino in prašiče.
It is very important that those antimicrobials are used in veterinary and human medicine according to responsible use principles to safeguard the efficacy of these substances and minimise the development of and dissemination of antimicrobial resistance.
Zelo pomembno je, da se navedena protimikrobna zdravila uporabljajo v veterinarski in humani medicini v skladu z načeli odgovorne uporabe za zaščito učinkovitosti teh snovi ter zmanjšanje razvoja in širjenja protimikrobne odpornosti.
In addition this process seems to be immediate which means that the overall time during which faeces of rabbits are exposed to enrofloxacin during treatment is not significantly higher than without the coprophagy practice.
Poleg tega se zdi, da je ta proces takojšen, kar pomeni, da skupni čas, v katerem so kunčji iztrebki med zdravljenjem izpostavljeni enrofloksacinu, ni bistveno daljši od časa izpostavljenosti brez prakse koprofagije.
Fluoroquinolones are also authorised for use in cattle, pigs and poultry.
Fluorokinoloni se lahko uporabljajo tudi pri govedu, prašičih in perutnini.
It should also be noted that coprophagy involves the ingestion of the own rabbit faeces and that there are no data to assess if this would have any impact on increase of resistance.
Opozoriti je treba tudi, da koprofagija vključuje zaužitje lastnih kunčjih iztrebkov in da niso na voljo nobeni podatki za oceno, ali to vpliva na povečanje odpornosti.
Taking into account the above reasoning the Committee considered that withdrawing or not authorising the use of these products in rabbit was considered not proportionate as this would create a negative impact on the availability of tools to treat respiratory diseases in this minor species, in cases when other antibiotics cannot be used or would not be sufficiently effective.
Odbor je ob upoštevanju zgornje utemeljitve menil, da bi bila ukinitev ali prepoved uporabe teh zdravil pri kuncih nesorazmerna, saj bi to negativno vplivalo na razpoložljivost orodij za zdravljenje bolezni dihal pri tej manj pomembni vrsti, kadar drugih antibiotikov ni mogoče uporabljati ali ti ne bi bili dovolj učinkoviti.
Restrictions on availability of antimicrobials for rabbits may cause animal health and welfare concerns.
Omejitev razpoložljivosti protimikrobnih zdravil pri kuncih lahko povzroči skrbi v zvezi z zdravjem živali in njihovim dobrim počutjem.
Grounds for maintaining the marketing authorisations
Razlogi za ohranitev dovoljenj za promet z zdravilom
The use of fluoroquinolones in rabbits may therefore have a higher risk on development of antimicrobial resistance, however this risk is theoretical.
Uporaba fluorokinolonov pri kuncih lahko zato pomeni večje tveganje za razvoj protimikrobne odpornosti, vendar je to tveganje teoretično.
However, data indicates that in the long run treatment could result in a decrease of efficacy of the treatment of the disease in rabbits and thus it is important that use is limited to cases where it is clearly needed and should be combined with good husbandry practices.
Vendar podatki kažejo, da bi lahko bila manjša učinkovitost zdravljenja bolezni pri kuncih dolgoročna posledica zdravljenja, zato ga je treba omejiti na primere, kjer je jasno potrebno, in ga izvajati skupaj z dobrimi živinorejskimi praksami.
Therefore, there are no data available to characterise the risk to public health specifically linked to intake of rabbit meat or contact with food producing rabbits.
Zato niso na voljo podatki za opredelitev tveganja za javno zdravje, ki je povezano zlasti z vnosom kunčjega mesa ali stikom s kunci za proizvodnjo živil.
Rabbits are raised in continuous systems where resistant bacteria might be persistent over time, however the overall risk would remain low due to the low consumption of rabbit meat.
Kunce vzrejajo v neprekinjenih sistemih, kjer so lahko ves čas prisotne odporne bakterije, vendar bi splošno tveganje zaradi nizke porabe kunčjega mesa ostalo nizko.
The evaluation of the risk related antimicrobial resistance has to consider both effects; on the target animal species and in humans.
V oceni protimikrobne odpornosti, povezane s tveganjem, je treba upoštevati oba učinka, in sicer na ciljno živalsko vrsto in na ljudi.
Enrofloxacin is for veterinary use only.
Enrofloksacin je namenjen samo uporabi v veterinarski medicini.
The practice of coprophagy (consumption of faeces) that is part of rabbits behaviour/physiology may hypothetically have an impact on development of antimicrobial resistance.
Koprofagija (uživanje iztrebkov), ki je del vedenja/fiziologije kuncev, lahko hipotetično vpliva na razvoj protimikrobne odpornosti.
Resistance transmission has not been studied specifically in rabbits.
Prenos odpornosti pri kuncih se ni posebej preučeval.
Data on susceptibility of enrofloxacin from a study conducted in Spain in 2005 showed a MIC90 of 0.06 µg/ml.
Podatki o občutljivosti za enrofloksacin iz študije, opravljene leta 2005 v Španiji, so pokazali, da je MIC90 0,06 µg/ml.
It is anticipated that the risk on individual level might be increased for rabbit as compared to other species.
Pričakuje se, da se bo lahko tveganje na individualni ravni pri kuncih povečalo v primerjavi z drugimi živalskimi vrstami.
The antimicrobial prudent use recommendations and warnings that are included in the product information are as follows:
Priporočila za preudarno uporabo protimikrobnih zdravil in opozorila o taki uporabi, ki so vključena v informacije o zdravilu, so:
Regarding the second risk, spread of resistant zoonotic bacteria and resistance genes via food, this is a well characterised risk for which CVMP in November 2006 recommended risk mitigation measures7.
Drugo navedeno tveganje, širitev odpornih zoonotskih bakterij in genov za odpornost s hrano, je dobro opredeljeno, zato je odbor CVMP novembra 2006 v zvezi z njim priporočil ukrepe za ublažitev tveganja7.
In another study carried out in Spain in 2011 to address the evolution of the level of resistances the MIC50 and the MIC90 of the P. multocida strains examined were 0.125 and 0.380 µg/ml, respectively.
V drugi študiji, ki je bila izvedena leta 2011 v Španiji za preučitev evolucije stopnje odpornosti, sta bila MIC50 in MIC90 preučevanih sevov P. multocida 0,125 oziroma 0,380 µg/ml.
In relation to the first risk, the use of fluoroquinolones is identified as a risk factor for spread of MRSA but this would be an issue mainly in case of high prevalence of MRSA in animals and/or close contact between animals and humans.
Glede na prvo tveganje je uporaba fluorokinolonov opredeljena kot dejavnik tveganja za širjenje MRSE, kar bi bilo problematično večinoma v primerih velike razširjenosti MRSE pri živalih ter/ali ob tesnem stiku med živalmi in ljudmi.
France considered that these resistances would possibly be directly or indirectly transmitted to humans and may represent a potential serious risk to public health as enrofloxacin belongs to the fluoroquinolones family which is considered a highly critical class of antimicrobials for human health.
Menila je tudi, da bi se lahko taka odpornost neposredno ali posredno prenesla na ljudi in bi lahko pomenila morebitno resno tveganje za javno zdravje, saj enrofloksacin spada v družino fluorokinolonov, ki je zelo pomemben razred protimikrobnih zdravil za človekovo zdravje.
• no additional risk management or mitigation measures nor prohibition of enrofloxacin in rabbits was considered proportionate;
• se je štelo, da sprejetje dodatnih ukrepov za obvladovanje ali zmanjšanje tveganja in prepoved uporabe enrofloksacina pri kuncih nista sorazmerni;
Risk to public health due to spread of resistant bacteria from treated animals Data from the RESAPATH 2009 and 2010 annual reports (French surveillance network for antimicrobial resistance in pathogenic bacteria of animal origin) were provided.
Tveganje za javno zdravje zaradi širjenja odpornih bakterij z zdravljenih živali Predloženi so bili podatki letnih poročil mreže RESAPATH (francoske mreže za spremljanje odpornosti patogenih bakterij živalskega izvora na protimikrobna zdravila) za leti 2009 in 2010.